China

China's life sciences ecosystem has rapidly evolved from a manufacturing-heavy sector into a world-class engine for biotechnology innovation and original drug discovery.

The nation is now globally recognized for its leadership in high-value biopharmaceuticals, particularly in the development of antibody-drug conjugates (ADCs), cell and gene therapies and metabolic health treatments.

This shift is supported by the NMPA’s streamlined regulatory pathways, which have significantly accelerated clinical trial enrollment and market approval for first-in-class therapies.

In the medical device sector, China is a pioneer in surgical robotics, AI-driven diagnostics and connected medtech solutions that integrate seamlessly with digital healthcare infrastructure.

Academic research in China continues to break boundaries, with major breakthroughs in genomics, protein folding and brain-computer interfaces emerging from its top-tier universities.

Strategic initiatives like Volume-Based Procurement (VBP) and the National Reimbursement Drug List (NRDL) are driving a "value-over-volume" transition, incentivizing domestic and international firms to focus on clinically differentiated assets.

Furthermore, the rise of AI-native drug discovery platforms has positioned China as a critical partner for global cross-border licensing deals and R&D collaborations.

With the rollout of the 15th Five-Year Plan, the country is further opening its scientific research facilities to international academia, solidifying its role as a central pillar of the global healthcare innovation landscape.